Altimmune, Inc. 8K

Altimmune reported positive Phase 2 RECLAIM trial results for pemvidutide in alcohol use disorder, meeting primary and key secondary endpoints and prompting plans for an End-of-Phase 2 FDA meeting.

On July 28, 2026, Altimmune, Inc. announced positive topline results from its RECLAIM Phase 2 clinical trial of pemvidutide, a balanced glucagon/GLP-1 dual receptor agonist, in patients with moderate to severe alcohol use disorder, reporting that the study met its primary endpoint with a highly statistically significant reduction in heavy drinking days versus placebo and achieved multiple key secondary endpoints recognized by the FDA as registrational, including two-level reductions in WHO risk drinking levels, zero heavy drinking days, improved abstinence rates, and reductions in PEth biomarkers and body weight, with a generally favorable tolerability profile; based on these data the company plans to request an End-of-Phase 2 meeting with the FDA to discuss the development path forward for pemvidutide in AUD and will present the results at future scientific venues.

Filing Facts

CIK

1326190

Ticker

ALT

Form

8K

Source Type

fda

Accession

0001326190-26-000044

Alert Tier

6